Today the biotech companies responsif GmbH and immatics biotechnologies GmbH disclosed the signing of a cooperation agreement within the scope of the BioChancePLUS grant program from the Federal Ministry of Education and Research (BMBF). The joint research project will focus on the application of technologies of both companies towards the preclinical development of a cancer vaccine.
